CD123+ acute myeloid leukemia

Clinical trials for CD123+ acute myeloid leukemia explained in plain language.

Never miss a new study

Get alerted when new CD123+ acute myeloid leukemia trials appear

Sign up with your email to follow new studies for CD123+ acute myeloid leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Phase 1 First-in-Human Multi-Region clinical trial of ORM-1153 in participants with relapsed or refractory acute myeloid leukemia (AML) or other hematological malignancies with CD123 expression

Not yet recruiting

The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid Leukemia (AML) which have a particular protein (called …

Matched conditions: CD123+ ACUTE MYELOID LEUKEMIA

Phase 1 • Sponsor: Orum Therapeutics USA, Inc.

Last updated Sep 09, 2026 17:00 UTC

CD123+ acute myeloid leukemia

Get alerted when new CD123+ acute myeloid leukemia trials appear

Phase 1 First-in-Human Multi-Region clinical trial of ORM-1153 in participants with relapsed or refractory acute myeloid leukemia (AML) or other hematological malignancies with CD123 expression